(Q37531720)

20 August 2017

1 reference

title

Enhancing immune responses to tumor-associated antigens (English)

1 reference

20 August 2017

Jack P Higgins

1

1 reference

20 August 2017

Michael B Bernstein

series ordinal

2

1 reference

20 August 2017

James W Hodge

series ordinal

3

1 reference

20 August 2017

publication date

1 August 2009

1 reference

Cancer Biology and Therapy

20 August 2017

published in

1 reference

20 August 2017

volume

8

1 reference

20 August 2017

issue

15

1 reference

20 August 2017

page(s)

1440-1449

1 reference

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

20 August 2017

cites work

1 reference

12 December 2020

Increase of CD4+ CD25+ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: a Phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+ CD25+ T lymphocytes

1 reference

12 December 2020

CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily

1 reference

12 December 2020

Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).

1 reference

12 December 2020

[Immunomodulation by cryosurgery in malignant melanoma]

1 reference

12 December 2020

Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.

1 reference

12 December 2020

Clinical investigations of Toll-like receptor agonists

1 reference

12 December 2020

Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.

1 reference

12 December 2020

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer

1 reference

12 December 2020

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

12 December 2020

Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs.

1 reference

12 December 2020

Calreticulin exposure dictates the immunogenicity of cancer cell death

1 reference

12 December 2020

Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges

1 reference

12 December 2020

Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma

1 reference

12 December 2020

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

1 reference

12 December 2020

Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation.

1 reference

12 December 2020

DAB(389)IL-2 (ONTAK): a novel fusion toxin therapy for lymphoma

1 reference

12 December 2020

Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.

1 reference

12 December 2020

Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis.

1 reference

12 December 2020

Lipid A and immunotherapy.

1 reference

12 December 2020

Depletion of CD4+ CD25+ regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes

1 reference

12 December 2020

Anti-cancer therapies targeting the tumor stroma

1 reference

12 December 2020

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer.

1 reference

12 December 2020

Regulatory T cells in ovarian cancer: biology and therapeutic potential

1 reference

12 December 2020

Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer

1 reference

12 December 2020

Alterations in host responsiveness in patients with prostatic cancer following cryosurgery or transurethral resection

1 reference

12 December 2020

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

1 reference

12 December 2020

The IL-12 family of cytokines in infection, inflammation and autoimmune disorders

1 reference

12 December 2020

Serum cytokine levels in response to hepatic cryoablation

1 reference

12 December 2020

Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression.

1 reference

12 December 2020

Transient T cell depletion causes regression of melanoma metastases

1 reference

12 December 2020

Phase I/II study of ipilimumab for patients with metastatic melanoma

1 reference

12 December 2020

Clinical safety of a viral vector based prostate cancer vaccine strategy

1 reference

12 December 2020

Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer

1 reference

12 December 2020

Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy

1 reference

12 December 2020

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma

1 reference

12 December 2020

Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial

1 reference

12 December 2020

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

1 reference

12 December 2020

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

1 reference

12 December 2020

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

1 reference

12 December 2020

Prostaglandins and cancer

1 reference

12 December 2020

The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot

1 reference

12 December 2020

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

12 December 2020

Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors

1 reference

12 December 2020

Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate

1 reference

12 December 2020

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

1 reference

12 December 2020

Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer.

1 reference

12 December 2020

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

1 reference

12 December 2020

Combination of radiofrequency ablation and immunotherapy.

1 reference

12 December 2020

CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

1 reference

12 December 2020

MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

1 reference

12 December 2020

Design of humanized antibodies: from anti-Tac to Zenapax

1 reference

12 December 2020

High-intensity focused ultrasound in the treatment of solid tumours.

1 reference

12 December 2020

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

1 reference

12 December 2020

Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation

1 reference

12 December 2020

Clinical development of MVA-based therapeutic cancer vaccines

1 reference

12 December 2020

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

1 reference

12 December 2020

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy

1 reference

12 December 2020

The role of NKT cells in tumor immunity

1 reference

12 December 2020

Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer

1 reference

12 December 2020

Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy

1 reference

12 December 2020

Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer.

1 reference

12 December 2020

The small-molecule immune response modifier imiquimod--its mode of action and clinical use in the treatment of skin cancer

1 reference

12 December 2020

IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells

1 reference

12 December 2020

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

1 reference

12 December 2020

Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor.

1 reference

12 December 2020

GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer

1 reference

12 December 2020

Multiple costimulatory modalities enhance CTL avidity

1 reference

12 December 2020

TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors

1 reference

12 December 2020

Immunity to tumour antigens.

1 reference

12 December 2020

Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey

1 reference

12 December 2020

Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide

1 reference

12 December 2020

Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results

1 reference

12 December 2020

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

1 reference

12 December 2020

Current treatment for liver metastases from colorectal cancer

1 reference

12 December 2020

COX-2 is expressed in human pulmonary, colonic, and mammary tumors.

1 reference

12 December 2020

Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. II. Effect of oestrogen, cryosurgery and transurethral resection on thymic-dependent lymphocytic blastogenesis

1 reference

12 December 2020

Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes

1 reference

12 December 2020

Targeting costimulatory pathways for tumor immunotherapy

1 reference

12 December 2020

The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand

1 reference

12 December 2020

Sensors of ionizing radiation effects on the immunological microenvironment of cancer

1 reference

12 December 2020

Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.

1 reference

12 December 2020

Select forms of tumor cell apoptosis induce dendritic cell maturation.

1 reference

12 December 2020

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer

1 reference

12 December 2020

IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets

1 reference

12 December 2020

Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma

1 reference

12 December 2020

Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma

1 reference

12 December 2020

Ipilimumab: controversies in its development, utility and autoimmune adverse events

1 reference

12 December 2020

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

1 reference

12 December 2020

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

12 December 2020

Prospects for CD40-directed experimental therapy of human cancer

1 reference

12 December 2020

Randomized clinical studies of anti-tumor vaccination: state of the art in 2008.

1 reference

12 December 2020

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

1 reference

12 December 2020

Hyperthermia on immune regulation: a temperature's story

1 reference

12 December 2020

Sipuleucel-T for the treatment of prostate cancer

1 reference

12 December 2020

Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients

1 reference

12 December 2020

Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles

1 reference

12 December 2020

Topical imiquimod: mechanism of action and clinical applications

1 reference

12 December 2020

Signalling pathways leading to IFN-alpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications

1 reference

12 December 2020

Peptide-based vaccines for cancer: realizing their potential

1 reference

12 December 2020

Increased Immunostimulatory Activity Conferred to Antigen-presenting Cells by Exposure to Antigen Extract From Hepatocellular Carcinoma After Radiofrequency Thermal Ablation

1 reference

12 December 2020

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

12 December 2020

Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo

1 reference

12 December 2020

Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.

1 reference

12 December 2020

Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use

1 reference

12 December 2020

Interleukin 21: combination strategies for cancer therapy

1 reference

12 December 2020

Human neoplasms elicit multiple specific immune responses in the autologous host

1 reference

12 December 2020

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

1 reference

12 December 2020

Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation

1 reference

12 December 2020

Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines

1 reference

12 December 2020

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

1 reference

12 December 2020

Lack of suppressive CD4+CD25+FOXP3+ T cells in advanced stages of primary cutaneous T-cell lymphoma.

1 reference

12 December 2020

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

12 December 2020

Immune therapy for cancer

1 reference

12 December 2020

Immunologic response to primary cryoablation of high-risk prostate cancer

1 reference

12 December 2020

Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients

1 reference

12 December 2020

Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells

1 reference

12 December 2020

The mode of action of immunological adjuvants

1 reference

12 December 2020

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

1 reference

12 December 2020

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

1 reference

12 December 2020

Extracorporeal high intensity focused ultrasound in the treatment of patients with solid malignancy

1 reference

12 December 2020

1 reference

12 December 2020

Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses

1 reference

12 December 2020

Coley's toxins, tumor necrosis factor and cancer research: a historical perspective

1 reference

12 December 2020

Identifiers

DOI

10.4161/CBT.8.15.9133

1 reference

20 August 2017

1 reference